|Bid||134.05 x 1100|
|Ask||137.00 x 800|
|Day's range||133.03 - 136.25|
|52-week range||117.08 - 374.58|
|Beta (5Y monthly)||0.03|
|PE ratio (TTM)||3.08|
|Earnings date||07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 June 2022|
|1y target est||233.03|
The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.
Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.
Data is still scarce on latest COVID-19 boosters